There are 3161 resources available
1248P - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis
Presenter: Xiaorong Dong
Session: Poster session 05
1249P - Health-related quality of life (HRQoL) at diagnosis for unresectable stage III NSCLC: Results from the French nationwide prospective study OBSTINATE (GFPC 06-2019)
Presenter: Charles Ricordel
Session: Poster session 05
1250P - Impact of systemic treatment on cardiac events following chemoradiotherapy in stage III lung cancer patients
Presenter: Judit Sanz Beltran
Session: Poster session 05
1251P - Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial
Presenter: Emanuela Olmetto
Session: Poster session 05
1252P - Stage III non-small cell lung cancer (NSCLC) in France, characteristics treatments and survival results of French real-world data
Presenter: Olivier Molinier
Session: Poster session 05
1260P - Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study
Presenter: Ludovic Doucet
Session: Poster session 05
1261P - Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations
Presenter: Jie Wang
Session: Poster session 05
1262P - Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance
Presenter: Tijmen van der Wel
Session: Poster session 05
1263P - Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)
Presenter: Hiroshige Yoshioka
Session: Poster session 05
1264P - Real-world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Presenter: John Heymach
Session: Poster session 05